Alimentiv, Inc.

Indero chose to expand into rheumatology because many inflammatory and autoimmune conditions that affect the skin also impact the musculoskeletal system.\n Montreal-based CRO Innovaderm Research has rebranded immediately to Indero, the latest change in an effort to become dually focused on both rheumatology and dermatology.As Innovaderm, Indero has 25 years of experience in clinical dermatology research, the company said in a March 7 release. The firm chose to expand into rheumatology because many inflammatory and autoimmune conditions that affect the skin also impact the musculoskeletal system, according to the release.“Our dual-focus, interdisciplinary approach allows us to support clinical studies for a wide range of rheumatology and dermatology conditions,” Indero CEO Jeff Smith said in the release. “The immune-mediated nature of both disease areas means that we are perfectly positioned to support clinical research across these specialties.” Smith took over the chief executive role from founder Robert Bissonnette, M.D., last month as part of Indero’s plan to specialize in both dermatology and rheumatology. Smith started his career at German pharma Bayer and then spent 12 years at gastrointestinal-focused CRO Alimentiv, including six and a half years as its CEO.Smith’s appointment followed the hiring of Ina Zschocke, Ph.D., as executive vice president of European operations and strategy in November 2024. Zschocke previously founded a dermatology CRO of her own called SCIderm.Indero operates in North America, Europe, Latin America and the Asia-Pacific region, according to its website.

The goal of the collaboration is to help Alimentiv’s biopharma customers overcome the challenges of current GI trial design. \n Gastrointestinal-focused CRO Alimentiv is upgrading its clinical trials with software firm PhaseV’s adaptive trial technology.In a new collaboration, Alimentiv will combine PhaseV\'s machine learning tech with its own full-service GI CRO offerings, the companies announced in a Feb. 3 release. The goal is to help Alimentiv’s biotech and pharma customers overcome the challenges of the current GI trial design.The trials will focus on inflammatory bowel disease (IBD), celiac disease, eosinophilic gastrointestinal disease and related diseases, according to the release. \"GI clinical trials have historically been limited by challenges such as patient variability, complex disease mechanisms and a lack of validated biomarkers,” PhaseV CEO Raviv Pryluk, Ph.D., said in the release. “These challenges often complicate efficacy assessments of new treatments and lead to trial failure.\"Other challenges that GI trials face include differences between patients, high placebo response rates in certain conditions like IBD, increasing study costs and lengthy trial timelines, the companies said in the release.PhaseV’s focus is on adaptive clinical trials, which means they use ongoing data collection to adjust study design, like changing the sample size or abandoning certain treatments or doses.Incorporating adaptive designs into its trials will allow Alimentiv to improve efficiency and provide patients with GI conditions better outcomes, according to the release. 

PhaseV's Adaptive Clinical Trials Platform Will Support the Gastrointestinal CRO in Addressing a Wide Range of GI-Related Conditions BOSTON , Feb. 3, 2025 /PRNewswire/ -- PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced today it has entered a strategic partnership with Alimentiv Inc., a global GI (gastrointestinal) contract research organization (CRO), to support the optimal design and execution of advanced adaptive clinical trials for a range of GI conditions. These trials will focus on inflammatory bowel disease (IBD), celiac disease, eosinophilic gastrointestinal disease (EGID) and other related disorders. The collaboration has the potential to accelerate the development of new GI therapies by leveraging adaptive trial methodologies that improve efficiency and outcomes for patients facing these challenging conditions. "Gastrointestinal diseases are on the rise, contributing to hundreds of thousands of deaths and costing an estimated $136B annually in the U.S. alone," said Pierre Gaudreault, CEO of Alimentiv. "By combining our expertise in GI with PhaseV's advanced machine learning capabilities for trial simulation, design and execution, we intend to significantly improve clinical study efficiency and outcomes. This will accelerate success for our sponsors and help address the growing burden of GI diseases more effectively." Designing and executing randomized control trials (RCTs) in the field of GI presents significant challenges. These include patient heterogeneity, high placebo response rates in conditions like inflammatory bowel disease, rising study costs, and lengthy trial timelines, all of which place strain on trial sponsors and hinder the discovery of new treatments. Advanced trial designs, such as adaptive designs, can help overcome these challenges by leveraging accumulating data throughout a trial to optimize design and execution. The collaboration incorporates PhaseV's proprietary adaptive clinical trial technology with Alimentiv's full-service GI CRO service offerings. The solution enables the optimal design of adaptive trials to meet the needs of these studies with seamless execution, helping pharmaceutical and biotech companies overcome the inherent challenges of current designs. "GI clinical trials have historically been limited by challenges such as patient variability, complex disease mechanisms and a lack of validated biomarkers. These challenges often complicate efficacy assessments of new treatments and lead to trial failure," said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. "Aligning our ML platform with Alimentiv's GI trial leadership will help trial sponsors overcome these challenges, enabling more robust trial designs and execution that increase the likelihood of success." About PhaseV Leveraging the power of advanced causal inference and pushing the boundaries of ML, PhaseV detects hidden signals in clinical data and extracts actionable insights for planning the optimal next steps. The company's technology enables optimal design and closed-loop execution of adaptive clinical trials, increasing efficiency and success rates. PhaseV is advancing paradigm shifts in the clinical trial world in order to bring new treatments to more patients in a more precise and efficient way. Learn more at and follow us on LinkedIn. About Alimentiv Inc. Alimentiv is a leading specialty GI-focused CRO advancing frontiers of gastrointestinal (GI) clinical trials and medical research since 1986. As a global CRO offering clinical, medical imaging and precision medicine services, Alimentiv partners with pharmaceutical and biotechnology industries to advance the development of novel therapies and accelerate their time to market. Alimentiv is headquartered in London, Ontario, Canada, with a global footprint across its operations in Canada, the United States, Europe, Asia-Pacific, and Latin America. For more information, visit: Media Contact: Ellie Hanson FINN Partners for PhaseV [email protected] 929-588-2008 Logo: SOURCE PhaseV; Alimentiv Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED